• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Hong Kong·Healthcare·3613.HK
Share

Beijing Tong Ren Tang Chinese Medicine Company Limited Stocks

HK$ 6.49Last Updated 19.08.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

HK$ 690.75M

HK$ 6.49
Key Takeaways

Risk factor

Limited trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Beijing Tong Ren Tang Chinese Medicine Company Limited, encompassing its various affiliates, specializes in the production, distribution, and direct sale of traditional Chinese medicine and wellness items, catering to both corporate distributors and individual consumers. Its operations are geographically segmented across Hong Kong, Mainland China, and international markets. Additionally, the company provides traditional Chinese medical consultations and therapeutic services. The firm maintains a network of 23 retail stores throughout Hong Kong, complemented by 46 international outlets located across Asia, Oceania, North America, and Europe. All its offerings are sold under the well-recognized Tong Ren Tang brand. Established in 1669, the company's main office is situated in Wan Chai, Hong Kong.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, undervalu

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 3613.HK is 10.5 and suggests 61% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

18.08.2026 15:23

Morning in New York: Focus on Rising Treasury Yields and Geopolitical Risks

18.08.2026 14:13

The "Panda" Loan: Why Yuan-Denominated Loans Are Attractive Not Only to Kazakhstan

18.08.2026 13:53

Druckenmiller sold Micron and Broadcom before the crash. What did he double down on?

18.08.2026 12:44

Yields on global government bonds have reached multi-year highs. What's going on?

18.08.2026 11:23

A malfunction in the rearview cameras forced Stellantis to recall nearly 1 million cars worldwide

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026